慢性淋巴细胞白血病患者的生存结果:一个SEER分析
Shivani Modi1, Srinishant Rajarajan2, Hardik Jain2
1Jefferson Einstein Healthcare Network, East Norriton, PA.
Clinical lymphoma, myeloma & leukemia
|August 31, 2025
概括
慢性淋巴细胞白血病 (CLL) 患者的存活率随着新疗法显著改善. 现代向治疗时代显示了CLL整体存活率的最显著增长.
科学领域:
- 血液学
- 癌症学
- 流行病学
背景情况:
- 慢性淋巴细胞白血病 (CLL) 是最常见的成人白血病.
- 从传统的化疗到化学免疫疗法和向药物治疗已经取得了进展.
- 评估实际生存结果对于了解治疗有效性至关重要.
研究的目的:
- 在不同治疗期内评估慢性淋巴细胞白血病 (CLL) 患者的生存结果.
- 评估新疗法对现实世界生存的影响.
- 分析基于人群的数据,重点是接受活跃全身治疗的患者.
主要方法:
- 使用SEER数据的回顾性队列研究 (1995-2020年).
- 将CLL患者分为三个阶段:前小说 (1995-2004),早期小说 (2005-2014) 和现代小说 (2015-2020).
- 从治疗开始分析整体存活率,考虑第一线治疗时代分配.
主要成果:
- 平均整体存活时间从3. 5年 (前小说) 增加到5. 2年 (早期小说) 和7. 8年 (现代小说).
- 晚期的死亡风险显著降低 (早期的aHR为0.75,现代的0.45).
- 在现代时代,完全响应率从15-20%上升到60%以上.
结论:
- 在不同治疗期的CLL患者中观察到显著的生存改善,特别是现代向治疗.
- 治疗的进步, 不仅仅是疾病生物学或患者选择,
- 尽管需要考虑COVID-19的影响,但支持继续开发新疗法.
更多相关视频
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
21.5K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
374
相关概念视频
Cancer Survival Analysis
448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
Comparing the Survival Analysis of Two or More Groups
280
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
280
Kaplan-Meier Approach
258
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
258
Actuarial Approach
132
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
132
Assumptions of Survival Analysis
196
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
196
